Genmab A/S reported a 25% increase in revenue for the first quarter of 2026 compared with the prior year [1].

The results highlight the company's reliance on high-performing cancer treatments to fuel its growth and fund the development of its late-stage pipeline.

Based in Copenhagen, Denmark, the biotechnology company saw worldwide net trade sales for Darzalex reach USD 3,964 million during the quarter ended March 31, 2026 [2]. This performance follows a strong 2025, in which the company recorded total revenue of $3.7 billion [5]. During that year, royalties from Darzalex specifically accounted for $2.4 billion [6].

Market analysts have responded to the company's trajectory with updated projections. Goldman Sachs set a price target of $30 per share for Genmab [4]. These figures suggest a significant jump over previous expectations; for instance, the consensus estimate for first-quarter revenue had been set at $0.89 billion [3].

The company's growth is attributed to the sustained demand for Darzalex and the ongoing momentum of other products like Epkinly. The reported revenue surge underscores the firm's ability to scale its commercial operations while advancing new therapies through clinical trials.

Genmab continues to leverage its royalty-based revenue model to maintain financial stability. By securing high-value trade sales in the first quarter, the company has established a capital cushion for its research and development efforts in the coming year.

“Revenue increased 25% compared with the prior year”

Genmab's financial results demonstrate a heavy reliance on a single blockbuster drug, Darzalex, to drive its valuation. While the 25% revenue growth and analyst upgrades indicate strong current market health, the company's long-term sustainability depends on whether its late-stage pipeline can successfully produce new revenue streams to diversify its portfolio beyond its current primary earners.